Literature DB >> 14513689

Technology evaluation: TNFerade, GenVec.

Ralf Kircheis1, Ernst Wagner.   

Abstract

TNFerade is a new gene therapy drug under development by GenVec that employs a replication-deficient adenovector carrying the gene for human tumor necrosis factor (TNF)-alpha, regulated by a radiation-sensitive promoter. TNFerade is currently undergoing phase II trials for the potential treatment of cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14513689

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  5 in total

1.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

Review 2.  Radiotherapy in Combination With Cytokine Treatment.

Authors:  Ondrej Palata; Nada Hradilova Podzimkova; Eva Nedvedova; Alexandra Umprecht; Lenka Sadilkova; Lenka Palova Jelinkova; Radek Spisek; Irena Adkins
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

3.  Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.

Authors:  Ling Li; Chun-li Zhang; Lei Kang; Rong-Fu Wang; Ping Yan; Qian Zhao; Lei Yin; Feng-qin Guo
Journal:  Cancer Biother Radiopharm       Date:  2015-09-18       Impact factor: 3.099

Review 4.  TNFerade, an innovative cancer immunotherapeutic.

Authors:  Arunava Kali
Journal:  Indian J Pharmacol       Date:  2015 Sep-Oct       Impact factor: 1.200

Review 5.  Nucleic Acid-Based Approaches for Tumor Therapy.

Authors:  Simone Hager; Frederic Julien Fittler; Ernst Wagner; Matthias Bros
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.